Ingrezza Sprinkle (Valbenazine Tosylate) Patent Expiration, LOE Window & CMS Spending
Ingrezza Sprinkle (Valbenazine Tosylate) by Neurocrine Biosciences: FDA Orange Book core substance LOE 2036-12-22 (last listed 2040-08-10), 1 AB generics, $4.2M 2024 CMS Part D & Medicaid spend, and $8,255 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Neurocrine Biosciences |
| FDA Application & Pathway | N218390 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2036-12-22 |
| Last Listed Patent or Exclusivity Date | 2040-08-10 |
| Orange Book Patents (*PED Extensions) | 22 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 1 |
| 2024 CMS Total Public Spend | $4.2M |
| 2024 Medicare Part D Spend | $3.6M |
| 2024 Medicaid Spend | $647K |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($8,255 intro WAC) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Neurocrine Biosciences across sibling Meru public-data platforms.